EX-99.2 3 a2021q4exhibit992.htm EX-99.2 Document

Exhibit 99.2


Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
FOURTH QUARTER
Percent Change
20212020TotalOperationsCurrency
Sales to customers by
geographic area
U.S.$12,163  11,809  3.0 % 3.0 — 
Europe 6,925  5,271 31.4  34.7  (3.3)
Western Hemisphere excluding U.S. 1,459  1,404  3.9  5.0  (1.1)
Asia-Pacific, Africa 4,257  3,991  6.6  9.0  (2.4)
International 12,641  10,666  18.5  21.2  (2.7)
      
Worldwide$24,804  22,475  10.4 % 11.6  (1.2)
        
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.






Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
TWELVE MONTHS
Percent Change
20212020TotalOperationsCurrency
Sales to customers by
geographic area
U.S.$47,156  43,133  9.3 % 9.3 — 
Europe 23,594  18,980  24.3  20.7  3.6
Western Hemisphere excluding U.S. 5,750  5,335  7.8  7.3  0.5
Asia-Pacific, Africa 17,275  15,136  14.1  11.4  2.7
International 46,619  39,451  18.2  15.3  2.9
      
Worldwide$93,775  82,584  13.6 % 12.2  1.4
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.


Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
FOURTH QUARTER
 Percent Change
20212020TotalOperationsCurrency
Sales to customers by
segment of business
Consumer Health
    U.S.$1,529 1,509 1.3 %1.3 — 
    International2,128 2,109 0.9 2.1 (1.2)
3,657    3,618 1.1 1.8 (0.7)
Pharmaceutical
    U.S.7,418 7,116 4.2 4.2— 
    International6,870 5,152 33.4 36.9(3.5)
14,288    12,268 16.5 17.9(1.4)
Medical Devices
    U.S.3,216    3,184 1.0 1.0 — 
    International3,643 3,405 7.0 9.3 (2.3)
 6,859    6,589 4.1 5.3 (1.2)
U.S.12,163 11,809 3.0 3.0 — 
International12,641 10,666 18.5 21.2 (2.7)
Worldwide$24,804 22,475 10.4 %11.6 (1.2)
   
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.





Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
TWELVE MONTHS
 Percent Change
20212020TotalOperationsCurrency
Sales to customers by
segment of business
Consumer Health
    U.S.$6,516 6,362 2.4 %2.4 — 
    International8,119 7,691 5.6 3.1 2.5 
14,635    14,053 4.1 2.8 1.3 
Pharmaceutical
    U.S.27,954 25,735 8.6 8.6— 
    International24,126 19,837 21.6 18.82.8 
52,080    45,572 14.3 13.11.2 
Medical Devices
    U.S.12,686    11,036 14.9 14.9 — 
    International14,374 11,923 20.6 17.3 3.3 
 27,060    22,959 17.9 16.2 1.7 
U.S.47,156 43,133 9.3 9.3 — 
International46,619 39,451 18.2 15.3 2.9 
Worldwide$93,775 82,584 13.6 %12.2 1.4 
   
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.


Johnson & Johnson and Subsidiaries 
Condensed Consolidated Statement of Earnings  
(Unaudited; in Millions Except Per Share Figures)
FOURTH QUARTER
20212020Percent
PercentPercentIncrease
Amountto SalesAmountto Sales(Decrease)
Sales to customers$24,804 100.0$22,475 100.010.4 
Cost of products sold7,955 32.17,814 34.81.8 
Gross Profit16,849 67.914,661 65.214.9 
Selling, marketing and administrative expenses7,154 28.96,457 28.710.8 
Research and development expense4,720 19.04,032 17.917.1 
In-process research and development00.037 0.2
Interest (income) expense, net47 0.274 0.3
Other (income) expense, net9 0.02,354 10.5
Restructuring83 0.360 0.3
Earnings before provision for taxes on income4,836 19.51,647 7.3193.6 
Provision for/(Benefit from) taxes on income100 0.4(91)(0.4)(209.9)
Net earnings$4,736 19.1$1,738 7.7172.5 
Net earnings per share (Diluted)$1.77 $0.65 172.3 
Average shares outstanding (Diluted)2,670.2 2,669.2 
Effective tax rate2.1 %(5.5)%
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$6,339 25.6$5,601 24.913.2 
Net earnings$5,678 22.9$4,965 22.114.4 
Net earnings per share (Diluted)$2.13 $1.86 14.5 
Effective tax rate10.4 %11.4 %
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.




Johnson & Johnson and Subsidiaries 
Condensed Consolidated Statement of Earnings  
(Unaudited; in Millions Except Per Share Figures)
TWELVE MONTHS
20212020Percent
PercentPercentIncrease
Amountto SalesAmountto Sales(Decrease)
Sales to customers$93,775 100.0$82,584 100.013.6 
Cost of products sold29,855 31.828,427 34.45.0 
Gross Profit63,920 68.254,157 65.618.0 
Selling, marketing and administrative expenses24,659 26.322,084 26.811.7 
Research and development expense14,714 15.712,159 14.721.0 
In-process research and development9001.0181 0.2  
Interest (income) expense, net130 0.190 0.1  
Other (income) expense, net489 0.52,899 3.5  
Restructuring252 0.3247 0.3
Earnings before provision for taxes on income22,776 24.316,497 20.038.1 
Provision for taxes on income1,898 2.01,783 2.2 6.4 
Net earnings$20,878 22.3$14,714 17.841.9 
Net earnings per share (Diluted)$7.81 $5.51 41.7 
Average shares outstanding (Diluted)2,674.0 2,670.7 
Effective tax rate8.3 %10.8 %
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$30,464 32.5$25,428 30.819.8 
Net earnings$26,195 27.9$21,433 26.022.2 
Net earnings per share (Diluted)$9.80 $8.03 22.0 
Effective tax rate14.0 %15.7 %
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.








Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Fourth Quarter
(Dollars in Millions Except Per Share Data)20212020
Net Earnings, after tax- as reported$4,736$1,738
Pre-tax Adjustments
Intangible Asset Amortization expense1,121 1,234
Litigation expense, net274 2,902
IPR&D0 37
Restructuring related140 85
Acquisition, integration and divestiture related 26 14
(Gains)/losses on securities (198)(373)
Medical Device Regulation 73 55
Consumer Health separation costs67 0
Tax Adjustments
Tax impact on special item adjustments 1
(184)(606)
Tax legislation and other tax related(377) (121)
Adjusted Net Earnings, after tax$5,678$4,965
Average shares outstanding (Diluted)2,670.2 2,669.2
Adjusted net earnings per share (Diluted)$2.13$1.86
Operational adjusted net earnings per share (Diluted)$2.18 
Notes:
1
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.




Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Twelve Months Ended
(Dollars in Millions Except Per Share Data)20212020
Net Earnings, after tax- as reported$20,878$14,714
Pre-tax Adjustments
Intangible Asset Amortization expense4,697 4,660
Litigation expense, net2,328 5,112
IPR&D 900 181
Restructuring related473 448
Acquisition, integration and divestiture related ¹(478)(1,073)
(Gains)/losses on securities (533)(547)
Medical Device Regulation 234 144
Consumer Health separation costs67 0
Other0 6
Tax Adjustments
Tax impact on special item adjustments 2
(1,281)(1,608)
Tax legislation and other tax related(1,090) (604)
Adjusted Net Earnings, after tax$26,195$21,433
Average shares outstanding (Diluted)2,674.0 2,670.7
Adjusted net earnings per share (Diluted)$9.80$8.03
Operational adjusted net earnings per share (Diluted)$9.65 
Notes:
1
Acquisition, integration and divestiture related for 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S. Acquisition, integration and divestiture related for 2020 primarily includes a Contingent Consideration reversal of $1,148M related to the timing of certain developmental milestones associated with the Auris Health acquisition.
2
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.







Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
 FOURTH QUARTER 2021 ACTUAL vs. 2020 ACTUAL
 Segments
Consumer Health Pharmaceutical  Medical Devices  Total
 WW As Reported 1.1 %16.5 %4.1 %10.4 %
 U.S. 1.3 %4.2 %1.0 %3.0 %
 International 0.9 %33.4 %7.0 %18.5 %
 WW Currency (0.7)(1.4)(1.2)(1.2)
 U.S. ————
 International (1.2)(3.5)(2.3)(2.7)
 WW Operational 1.8 %17.9 %5.3 %11.6 %
 U.S. 1.3 %4.2 %1.0 %3.0 %
 International 2.1 %36.9 %9.3 %21.2 %
General Surgery
Advanced Sterilization Products0.30.1
 U.S. 0.00.0
 International 0.50.2
Skin Health / Beauty
Dr. Ci Labo - Sedona0.70.1
 U.S. 0.00.0
 International 1.20.3
All Other Acquisitions and Divestitures0.40.70.10.4
 U.S. 0.60.00.20.1
 International 0.31.70.00.8
WW Adjusted Operational2.9 %18.6 %5.6 %12.3 %
 U.S. 1.9 %4.2 %1.2 %3.1 %
 International 3.6 %38.6 %9.8 %22.4 %
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
TWELVE MONTHS 2021 ACTUAL vs. 2020 ACTUAL
 Segments
Consumer Health Pharmaceutical  Medical Devices  Total
 WW As Reported 4.1 %14.3 %17.9 %13.6 %
 U.S. 2.4 %8.6 %14.9 %9.3 %
 International 5.6 %21.6 %20.6 %18.2 %
 WW Currency 1.31.21.71.4
 U.S. ————
 International 2.52.83.32.9
 WW Operational 2.8 %13.1 %16.2 %12.2 %
 U.S. 2.4 %8.6 %14.9 %9.3 %
 International 3.1 %18.8 %17.3 %15.3 %
General Surgery
Advanced Sterilization Products0.50.1
 U.S. 0.00.0
 International 1.00.3
Skin Health / Beauty
Dr. Ci Labo - Sedona0.50.1
U.S.0.00.0
International1.00.2
All Other Acquisitions and Divestitures0.40.50.10.4
 U.S. 0.60.00.40.2
 International 0.31.40.00.8
WW Adjusted Operational3.8 %13.6 %16.8 %12.8 %
 U.S. 3.0 %8.6 %15.3 %9.5 %
 International 4.4 %20.2 %18.3 %16.6 %
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.



Johnson & Johnson
Segment Sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20212020Reported
Operational (1)
Currency
CONSUMER HEALTH SEGMENT (2)
OTC
US$63354316.8 %16.8 %— %
Intl74064215.1 14.9 0.2 
WW1,3731,18515.9 15.8 0.1 
SKIN HEALTH / BEAUTY
US538583(7.8)(7.8)— 
Intl546594(8.2)(6.4)(1.8)
WW1,084 1,177(8.0)(7.1)(0.9)
ORAL CARE
US159173(8.2)(8.2)— 
Intl246264(7.2)(5.5)(1.7)
WW405 437 (7.6)(6.5)(1.1)
BABY CARE
US9097(7.5)(7.5)— 
Intl309310(0.3)1.3 (1.6)
WW399 407 (2.0)(0.8)(1.2)
WOMEN'S HEALTH
US4314.1 14.1 — 
Intl230234(1.8)1.2 (3.0)
WW233237(1.6)1.3 (2.9)
WOUND CARE / OTHER
US106110(4.2)(4.2)— 
Intl5765(9.6)(10.2)0.6 
WW164175(6.2)(6.4)0.2 
TOTAL CONSUMER HEALTH
US1,529 1,509 1.3 1.3 — 
Intl2,128 2,109 0.9 2.1 (1.2)
WW$3,657 3,618 1.1 %1.8 %(0.7)%
See footnotes at end of schedule





Johnson & Johnson
Segment Sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US$2,9122,8452.4 %2.4 %— %
Intl1,4431,26114.5 17.9 (3.4)
WW4,3554,1056.1 7.1 (1.0)
     REMICADE
     US511656(22.2)(22.2)— 
     US Exports (4)
392553.5 53.5 — 
     Intl214220(2.3)(2.4)0.1 
     WW764901(15.2)(15.2)0.0 
     SIMPONI / SIMPONI ARIA
     US287315(8.9)(8.9)— 
     Intl2712613.6 8.4 (4.8)
     WW559576(3.2)(1.0)(2.2)
     STELARA
     US1,5421,572(1.9)(1.9)— 
     Intl79267217.9 21.7 (3.8)
     WW2,3342,2444.0 5.1 (1.1)
     TREMFYA
     US528 276 90.9 90.9 — 
     Intl165 105 56.9 61.8 (4.9)
     WW693 382 81.5 82.8 (1.3)
     OTHER IMMUNOLOGY
     US6 — **— 
     Intl— 2 ***
     WW6 2 ***
INFECTIOUS DISEASES
US61447030.8 30.8 — 
Intl1,824442**(3.0)
WW2,437912**(1.5)
     COVID-19 VACCINE
     US213—**— 
     Intl1,405—**— 
     WW1,619—**— 
     EDURANT / rilpivirine
     US10 11 (15.8)(15.8)— 
     Intl220 236 (6.8)(3.3)(3.5)
     WW230 248 (7.2)(3.9)(3.3)
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     US380433(12.2)(12.2)— 
     Intl135136(0.1)3.0 (3.1)
     WW515569(9.3)(8.5)(0.8)
     OTHER INFECTIOUS DISEASES
     US1125(55.9)(55.9)— 
     Intl6371(10.9)(10.0)(0.9)
     WW7496(22.9)(22.2)(0.7)
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
NEUROSCIENCE
US$89980611.4 %11.4%—%
Intl8948920.23.2(3.0)
WW1,7931,6985.57.1(1.6)
     CONCERTA / methylphenidate
     US553368.1 68.1—
     Intl1231203.26.0(2.8)
     WW17815317.219.4(2.2)
     INVEGA SUSTENNA / XEPLION / INVEGA
     TRINZA / TREVICTA
     US6686109.59.5—
     Intl361355 1.55.0(3.5)
     WW1,0299656.57.8(1.3)
     RISPERDAL CONSTA
     US77762.32.3—
     Intl6392(30.3)(26.4)(3.9)
     WW140167(15.6)(13.4)(2.2)
     OTHER NEUROSCIENCE
     US998811.711.7—
     Intl3463266.28.6(2.4)
     WW4454147.49.2(1.8)
ONCOLOGY
US1,5941,4698.58.5—
Intl2,184 1,965 11.115.2(4.1)
WW3,7783,43410.012.3(2.3)
     DARZALEX
     US867 692 25.325.3—
     Intl778 561 38.943.5(4.6)
     WW1,645 1,253 31.433.4(2.0)
     ERLEADA
     US235 176 33.433.4—
     Intl149 64 ***
     WW384 241 59.861.3(1.5)
     IMBRUVICA
     US436 492 (11.3)(11.3)—
     Intl626 625 0.03.4(3.4)
     WW1,062 1,117 (5.0)(3.1)(1.9)
     ZYTIGA / abiraterone acetate
     US2389 (74.2)(74.2)—
     Intl525533(1.4)3.1(4.5)
     WW548622(11.8)(7.9)(3.9)
     OTHER ONCOLOGY
     US34 20 64.764.7—
     Intl106183(42.0)(39.2)(2.8)
     WW140202(31.3)(28.8)(2.5)
See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
PULMONARY HYPERTENSION
US$587 592 (0.7)%(0.7)%— %
Intl264 273 (3.6)0.8 (4.4)
WW851 865 (1.6)(0.2)(1.4)
     OPSUMIT
     US286 279 2.0 2.0 — 
     Intl162 173 (6.1)(1.7)(4.4)
     WW448 452 (1.1)0.6 (1.7)
     UPTRAVI
     US264 263 0.0 0.0 — 
     Intl46 38 21.9 24.7 (2.8)
     WW310 301 2.7 3.1 (0.4)
     OTHER PULMONARY HYPERTENSION
     US38 49 (20.1)(20.1)— 
     Intl56 63 (12.2)(6.6)(5.6)
     WW94 112 (15.6)(12.4)(3.2)
CARDIOVASCULAR / METABOLISM / OTHER
US813935(13.1)(13.1)— 
Intl261317(17.8)(16.0)(1.8)
WW1,0741,253(14.3)(13.8)(0.5)
     XARELTO
     US644 629 2.5 2.5 — 
     Intl— — — — — 
     WW644 629 2.5 2.5 — 
     INVOKANA / INVOKAMET
     US59 159 (63.1)(63.1)— 
     Intl60 58 3.8 4.5 (0.7)
     WW120 217 (45.1)(44.9)(0.2)
     PROCRIT / EPREX
     US55 62 (12.8)(12.8)— 
     Intl58 66 (13.0)(11.7)(1.3)
     WW113 129 (12.9)(12.2)(0.7)
     OTHER
     US55 85 (35.6)(35.6)— 
     Intl143 194 (25.9)(23.8)(2.1)
     WW198 278 (28.9)(27.4)(1.5)
TOTAL PHARMACEUTICAL
US7,4187,1164.2 4.2 — 
Intl6,8705,15233.4 36.9 (3.5)
WW$14,28812,26816.5 %17.9 %(1.4)%
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20212020Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2)
INTERVENTIONAL SOLUTIONS
US$483 433 11.6 %11.6 %— %
Intl536 46016.5 18.8 (2.3)
WW1,019 89314.1 15.3 (1.2)
ORTHOPAEDICS
US1,305 1,352 (3.5)(3.5)— 
Intl851 839 1.5 3.9 (2.4)
WW2,155 2,191 (1.6)(0.7)(0.9)
     HIPS
     US229 229 0.4 0.4 — 
     Intl151 143 4.9 6.5 (1.6)
     WW380 372 2.1 2.7 (0.6)
     KNEES
     US208 216 (4.2)(4.2)— 
     Intl135 129 4.66.5 (1.9)
     WW342 345 (0.9)(0.2)(0.7)
     TRAUMA
     US467 454 2.8 2.8 — 
     Intl261 268 (2.4)0.7 (3.1)
     WW728 722 0.9 2.0 (1.1)
     SPINE, SPORTS & OTHER
     US401 453 (11.4)(11.4)— 
     Intl304 299 2.0 4.3 (2.3)
     WW706 752 (6.1)(5.2)(0.9)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
FOURTH QUARTER
% Change
20212020Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2) (Continued)
SURGERY
US$986 1,002 (1.7)(1.7)— %
Intl1,527 1,427 7.0 8.7 (1.7)
WW2,513 2,429 3.5 4.4 (0.9)
     ADVANCED
US457 456 0.5 0.5 — 
Intl735 660 11.2 12.6 (1.4)
WW1,192 1,116 6.8 7.6 (0.8)
     GENERAL
US528 546 (3.4)(3.4)— 
Intl793 767 3.4 5.3 (1.9)
WW1,321 1,312 0.6 1.7 (1.1)
VISION
US443 397 11.4 11.4 — 
Intl728 679 7.2 10.8 (3.6)
WW1,171 1,076 8.7 11.0 (2.3)
     CONTACT LENSES / OTHER
US316 289 9.4 9.4 — 
Intl518 507 1.9 5.8 (3.9)
WW833 796 4.6 7.1 (2.5)
     SURGICAL
US126 108 16.816.8— 
Intl211 172 22.925.4 (2.5)
WW338 280 20.522.1(1.6)
TOTAL MEDICAL DEVICES
US3,216 3,184 1.0 1.0 — 
Intl3,643 3,405 7.0 9.3 (2.3)
WW$6,859 6,589 4.1 %5.3 %(1.2)%
See footnotes at end of schedule







Johnson & Johnson
Segment Sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20212020Reported
Operational (1)
Currency
CONSUMER HEALTH SEGMENT (2)
OTC
US$2,5942,4605.4 %5.4 %— %
Intl2,6342,36411.4 6.9 4.5 
WW5,2274,8248.4 6.2 2.2 
SKIN HEALTH / BEAUTY
US2,4002,3502.1 2.1 — 
Intl2,1412,1001.9 (0.3)2.2 
WW4,541 4,4502.0 1.0 1.0 
ORAL CARE
US637683(6.7)(6.7)— 
Intl1,0089585.1 2.8 2.3 
WW1,645 1,641 0.2 (1.2)1.4 
BABY CARE
US3783760.5 0.5 — 
Intl1,1881,1414.1 3.7 0.4 
WW1,566 1,517 3.2 2.9 0.3 
WOMEN'S HEALTH
US1313(1.6)(1.6)— 
Intl9058881.8 2.0 (0.2)
WW9179011.8 1.9 (0.1)
WOUND CARE / OTHER
US4954803.1 3.1 — 
Intl2432401.7 (2.7)4.4 
WW7397202.6 1.2 1.4 
TOTAL CONSUMER HEALTH
US6,516 6,362 2.4 2.4 — 
Intl8,119 7,691 5.6 3.1 2.5 
WW$14,635 14,053 4.1 %2.8 %1.3 %
See footnotes at end of schedule





Johnson & Johnson
Segment Sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US$10,84310,1756.6 %6.6 %— %
Intl5,9074,88021.0 17.7 3.3 
WW16,75015,05511.3 10.2 1.1 
     REMICADE
     US2,0192,508(19.5)(19.5)— 
     US Exports (4)
236346(31.9)(31.9)— 
     Intl9358934.8 0.4 4.4 
     WW3,1903,747(14.9)(15.9)1.0 
     SIMPONI / SIMPONI ARIA
     US1,1271,155(2.4)(2.4)— 
     Intl1,1481,0885.5 4.1 1.4 
     WW2,2762,2431.4 0.8 0.6 
     STELARA
     US5,9385,24013.3 13.3 — 
     Intl3,1962,46729.6 25.9 3.7 
     WW9,1347,70718.5 17.3 1.2 
     TREMFYA
     US1,503 926 62.3 62.3 — 
     Intl624 421 48.2 44.0 4.2 
     WW2,127 1,347 57.9 56.5 1.4 
     OTHER IMMUNOLOGY
     US21 — **— 
     Intl3 11 (73.3)(74.6)1.3 
     WW24 11 ***
INFECTIOUS DISEASES
US2,2491,73529.7 29.7 — 
Intl3,6121,83996.3 93.4 2.9 
WW5,8613,57464.0 62.5 1.5 
     COVID-19 VACCINE
     US634—**— 
     Intl1,751—**— 
     WW2,385—**— 
     EDURANT / rilpivirine
     US41 44 (7.6)(7.6)— 
     Intl953 920 3.6 0.4 3.2 
     WW994 964 3.1 0.0 3.1 
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     US1,5081,587(4.9)(4.9)— 
     Intl575597(3.6)(6.0)2.4 
     WW2,0832,184(4.6)(5.2)0.6 
     OTHER INFECTIOUS DISEASES
     US66104(36.0)(36.0)— 
     Intl3333233.0 (0.1)3.1 
     WW399427(6.5)(8.9)2.4 
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
NEUROSCIENCE
US$3,3473,0918.3 %8.3 %— %
Intl3,6643,4576.0 3.9 2.1
WW7,0116,5487.1 5.9 1.2
     CONCERTA / methylphenidate
     US172183(5.8)(5.8)—
     Intl49543912.810.12.7
     WW6676227.35.41.9
     INVEGA SUSTENNA / XEPLION / INVEGA
     TRINZA / TREVICTA
     US2,5502,31410.2 10.2 —
     Intl1,4721,339 10.0 6.9 3.1
     WW4,0223,65310.1 9.0 1.1
     RISPERDAL CONSTA
     US287296(2.9)(2.9)—
     Intl305346(11.8)(13.1)1.3
     WW592642(7.7)(8.4)0.7
     OTHER NEUROSCIENCE
     US33829813.313.3—
     Intl1,3911,3344.33.21.1
     WW1,7291,6326.05.01.0
ONCOLOGY
US5,9585,09217.017.0—
Intl8,590 7,275 18.115.32.8
WW14,54812,36717.616.01.6
     DARZALEX
     US3,169 2,232 42.042.0—
     Intl2,854 1,958 45.842.63.2
     WW6,023 4,190 43.842.31.5
     ERLEADA
     US813 583 39.339.3—
     Intl478 176 ***
     WW1,291 760 70.068.71.3
     IMBRUVICA
     US1,747 1,821 (4.0)(4.0)—
     Intl2,622 2,307 13.610.43.2
     WW4,369 4,128 5.84.11.7
     ZYTIGA / abiraterone acetate
     US119 373 (68.1)(68.1)—
     Intl2,1782,0973.91.52.4
     WW2,2972,470(7.0)(9.0)2.0
     OTHER ONCOLOGY
     US110 83 31.731.7—
     Intl458738(37.9)(38.7)0.8
     WW568821(30.8)(31.5)0.7
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
PULMONARY HYPERTENSION
US$2,365 2,133 10.9 %10.9 %— %
Intl1,085 1,015 6.9 5.5 1.4 
WW3,450 3,148 9.6 9.2 0.4 
     OPSUMIT
     US1,147 1,008 13.7 13.7 — 
     Intl672 631 6.6 5.1 1.5 
     WW1,819 1,639 11.0 10.4 0.6 
     UPTRAVI
     US1,056 955 10.5 10.5 — 
     Intl181 138 31.1 27.0 4.1 
     WW1,237 1,093 13.1 12.6 0.5 
     OTHER PULMONARY HYPERTENSION
     US163 169 (3.7)(3.7)— 
     Intl232 247 (5.9)(5.4)(0.5)
     WW395 416 (5.0)(4.7)(0.3)
CARDIOVASCULAR / METABOLISM / OTHER
US3,1923,509(9.0)(9.0)— 
Intl1,2681,369(7.4)(10.9)3.5 
WW4,4604,878(8.6)(9.6)1.0 
     XARELTO
US2,438 2,345 4.0 4.0 — 
Intl— — — — — 
WW2,438 2,345 4.0 4.0 — 
     INVOKANA / INVOKAMET
US308 564 (45.4)(45.4)— 
Intl254 231 9.9 5.4 4.5 
WW563 795 (29.3)(30.6)1.3 
     PROCRIT / EPREX
US223 277 (19.7)(19.7)— 
Intl256 274 (6.8)(10.1)3.3 
WW479 552 (13.3)(14.9)1.6 
     OTHER
US223 323 (31.0)(31.0)— 
Intl758 864 (12.2)(15.5)3.3 
WW981 1,186 (17.3)(19.7)2.4 
TOTAL PHARMACEUTICAL
US27,95425,7358.6 8.6 — 
Intl24,12619,83721.6 18.8 2.8 
WW$52,08045,57214.3 %13.1 %1.2 %
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20212020Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2)
INTERVENTIONAL SOLUTIONS
US$1,836 1,452 26.4 %26.4 %— %
Intl2,1351,59434.0 29.8 4.2 
WW3,9713,04630.4 28.2 2.2 
ORTHOPAEDICS
US5,126 4,779 7.3 7.3 — 
Intl3,462 2,984 16.0 12.1 3.9 
WW8,588 7,763 10.6 9.1 1.5 
     HIPS
     US883 793 11.4 11.4 — 
     Intl602 487 23.6 18.9 4.7 
     WW1,485 1,280 16.0 14.3 1.7 
     KNEES
     US787 743 5.9 5.9 — 
     Intl538 427 26.1 21.7 4.4 
     WW1,325 1,170 13.3 11.7 1.6 
     TRAUMA
     US1,819 1,648 10.4 10.4 — 
     Intl1,066 966 10.4 7.1 3.3 
     WW2,885 2,614 10.4 9.2 1.2 
     SPINE, SPORTS & OTHER
     US1,637 1,595 2.6 2.6 — 
     Intl1,256 1,104 13.8 9.9 3.9 
     WW2,893 2,699 7.2 5.6 1.6 
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
TWELVE MONTHS
% Change
20212020Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2) (Continued)
SURGERY
US$3,867 3,249 19.0 %19.0 %— %
Intl5,945 4,983 19.3 15.6 3.7 
WW9,812 8,232 19.2 17.0 2.2 
     ADVANCED
US1,761 1,535 14.9 14.9 — 
Intl2,861 2,304 24.1 20.0 4.1 
WW4,622 3,839 20.4 18.0 2.4 
     GENERAL
US2,105 1,714 22.7 22.7 — 
Intl3,085 2,679 15.2 11.8 3.4 
WW5,190 4,392 18.1 16.1 2.0 
VISION
US1,857 1,557 19.3 19.3 — 
Intl2,831 2,362 19.8 18.8 1.0 
WW4,688 3,919 19.6 19.0 0.6 
     CONTACT LENSES / OTHER
US1,398 1,213 15.2 15.2 — 
Intl2,043 1,781 14.7 14.0 0.7 
WW3,440 2,994 14.9 14.5 0.4 
     SURGICAL
US459 344 33.5 33.5 — 
Intl788 581 35.7 33.3 2.4 
WW1,248 925 34.9 33.4 1.5 
TOTAL MEDICAL DEVICES
US12,686 11,036 14.9 14.9 — 
Intl14,374 11,923 20.6 17.3 3.3 
WW$27,060 22,959 17.9 %16.2 %1.7 %
Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-
rounded figures and, therefore, may not recalculate precisely.
The Company estimates that the inclusion of an additional week in the 2020 fiscal year impacted fiscal fourth quarter 2021 comparative sales growth by approximately -4% and full year fiscal 2021 comparative sales growth by approximately -1%.
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales